共 50 条
- [21] Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate CancerJOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (06) : 2429 - 2446Liedtke, Andy J.Adeniji, Adegoke O.Chen, MoByrns, Michael C.Jin, YiChristianson, David W.Marnett, Lawrence J.Penning, Trevor M.
- [22] In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2014, 141 : 44 - 51Roy, JennyFournier, Michelle-AudreyMaltais, ReneKenmogne, Lucie CarollePoirier, Donald
- [23] 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: Highly Potent and Selective Inhibitors of the Type 5 17-β-Hydroxysteroid Dehydrogenase AKR1C3JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (17) : 7746 - 7758Jamieson, Stephen M. F.Brooke, Darby G.Heinrich, DanielAtwell, Graham J.Silva, ShevanHamilton, Emma J.Turnbull, Andrew P.Rigoreau, Laurent J. M.Trivier, ElisabethSoudy, ChristelleSamlal, Sharon S.Owen, Paul J.Schroeder, EwaldRaynham, TonyFlanagan, Jack U.Denny, William A.
- [24] XL903, a Potent, Selective and Orally Bioavailable 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor for the Treatment of Metabolic Disease.ENDOCRINE REVIEWS, 2010, 31 (03)Dalgard, J.Bollu, V.Flatt, B.Hogue, A.Huang, H-JLi, J.Li, J.Mohan, R.Murray, I.Willy, P.Ogilvie, K. M.
- [25] Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): Role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogsCHEMICO-BIOLOGICAL INTERACTIONS, 2009, 178 (1-3) : 221 - 227Byrns, Michael C.Penning, Trevor M.
- [26] Type 2 3a/Type 5 17β-HSD (AKR1C3) Is a Negative Regulator of Breast Cancer Proliferation: An Immunohistochemical and In Vitro StudyMODERN PATHOLOGY, 2012, 25 : 55A - 55AMurugan, P.Lin, H-KWu, W.Miller, V.Yang, Q.Fung, K-M
- [27] Type 2 3a/Type 5 17β-HSD (AKR1C3) Is a Negative Regulator of Breast Cancer Proliferation: An Immunohistochemical and In Vitro StudyLABORATORY INVESTIGATION, 2012, 92 : 55A - 55AMurugan, P.Lin, H-KWu, W.Miller, V.Yang, Q.Fung, K-M
- [28] SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivoCANCER LETTERS, 2014, 351 (01) : 143 - 150Wang, LuAi, JingShen, YanyanZhang, HaotianPeng, XiaHuang, MinZhang, AoDing, JianGeng, Meiyu
- [29] STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer modelENDOCRINE-RELATED CANCER, 2013, 20 (01) : 53 - 64Day, Joanna M.Foster, Paul A.Tutill, Helena J.Schmidlin, FabienSharland, Christopher M.Hargrave, Jonathan D.Vicker, NigelPotter, Barry V. L.Reed, Michael J.Purohit, Atul
- [30] In vitro and in vivo antitumor activity of TH3424: Preclinical rationale for a highly selective AKR1C3 prod rug for treating hepatocellular carcinomasCANCER RESEARCH, 2016, 76Duan, JianxinWang, ZhongLi, QingCao, YeyuHe, PingMeng, FanyingZhou, ChanghuaWang, YanhongQu, GavinLi, HenryLi, JiangYang, MengQi, HuiJung, DonSong, MeiMatteucci, Mark